1. Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?

   • Chao-Hua Chiu
   • Teh-Ying Chou
   • Chun-Ming Tsai

   Review Article 23 July 2014 Pages: 661 - 665

   

2. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil

   • David Jamieson
   • Jo Lee
   • Alan V. Boddy

   Original Article 24 July 2014 Pages: 667 - 674

   

3. Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy

   • Dorothy M. Keefe
   • Linda S. Elting
   • Stephen T. Sonis

   Original Article 25 July 2014 Pages: 675 - 680

   

4. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer

   • Eleazar Omar Macedo-Pérez
   • Vicente Morales-Oyarvide
   • Oscar Arrieta

   Original Article 25 July 2014 Pages: 681 - 690

   

5. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)

   • Chang Xia
   • Roberto Leon-Ferre
   • Mohammed Milhem

   Original Article Open access 26 July 2014 Pages: 691 - 697

   

6. Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study

   • Shogo Kobayashi
   • Hiroaki Nagano
   • Tatsuya Ioka

   Original Article 30 July 2014 Pages: 699 - 709

   

7. Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model

   • Marcelo Leite Vieira Costa
   • Roberto César Pereira Lima-Júnior
   • Ronaldo Albuquerque Ribeiro

   Original Article 01 August 2014 Pages: 711 - 720

   

8. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901

   • Kosuke Takahashi
   • Hiroshi Saito
   • Ryujiro Suzuki

   Original Article 03 August 2014 Pages: 721 - 727

   

9. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies

   • Jean-Pascal Machiels
   • Arthur Staddon
   • Sunil Sharma

   Original Article 07 August 2014 Pages: 729 - 737

   

10. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

    • Robert J. Motzer
    • Thomas E. Hutson
    • J. Andrew Williams

    Original Article Open access 07 August 2014 Pages: 739 - 750

    

11. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study

    • Zuleyha Akgun
    • Sezer Saglam
    • Esra Kaytan-Saglam

    Original Article 08 August 2014 Pages: 751 - 756

12. Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy

    • Göran Carlsson
    • Elisabeth Odin
    • Yvonne Wettergren

    Original Article 08 August 2014 Pages: 757 - 763

    

13. A pharmacodynamic model of Bcr–Abl signalling in chronic myeloid leukaemia

    • Robert C. Jackson
    • Tomas Radivoyevitch

    Original Article 09 August 2014 Pages: 765 - 776

    

14. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy

    • Zheng Li
    • Yi Qing
    • Dong Wang

    Original Article 09 August 2014 Pages: 777 - 786

    

15. Anticancer activity of VDR-coregulator inhibitor PS121912

    • Preetpal S. Sidhu
    • Kelly Teske
    • Leggy A. Arnold

    Original Article 09 August 2014 Pages: 787 - 798

    

16. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane

    • Ji Soo Park
    • Hei-Cheul Jeung
    • Hyun Cheol Chung

    Original Article 09 August 2014 Pages: 799 - 808

    

17. Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells

    • Gisela Gutiérrez-Iglesias
    • Yamilec Hurtado
    • Rebeca López-Marure

    Original Article 12 August 2014 Pages: 809 - 817

    

18. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors

    • Amit Garg
    • Angelica Quartino
    • Bert Lum

    Original Article 14 August 2014 Pages: 819 - 829

    

19. Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group

    • Patrick Thompson
    • Heather E. Wheeler
    • Stacey L. Berg

    Original Article 14 August 2014 Pages: 831 - 838

    

20. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer

    • Qiang Zhang
    • Xiaoli Zhu
    • Yong Lin

    Original Article Open access 14 August 2014 Pages: 839 - 846

    

21. The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma

    • Ana S. Soares
    • Vera M. Costa
    • Paula Fresco

    Original Article 14 August 2014 Pages: 847 - 860

    

22. A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer

    • Hee Man Kim
    • Kyong Joo Lee
    • Seung Woo Park

    Original Article 17 August 2014 Pages: 861 - 865

    

23. The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors

    • Sunil Sharma
    • Carolyn D. Britten
    • Daniel George

    Clinical Trial Report 06 September 2014 Pages: 867 - 874

    

24. Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network

    • Natalie Callander
    • Stephanie Markovina
    • Shigeki Miyamoto

    Clinical Trial Report Open access 29 August 2014 Pages: 875 - 882